Comparative Pharmacology
Head-to-head clinical analysis: LANTUS SOLOSTAR versus TOUJEO SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANTUS SOLOSTAR versus TOUJEO SOLOSTAR.
LANTUS SOLOSTAR vs TOUJEO SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog with prolonged duration of action. It binds to insulin receptors, activating downstream signaling pathways including PI3K/Akt, leading to increased glucose uptake in peripheral tissues, inhibition of hepatic gluconeogenesis, and promotion of glycogenesis and lipogenesis. The long-acting profile is due to precipitation at subcutaneous injection site with slow absorption.
Insulin glargine is a long-acting human insulin analog that binds to the insulin receptor, activating cellular glucose uptake and inhibiting hepatic glucose production.
Injection, subcutaneous: initial: 0.2 units/kg once daily, typical maintenance: 0.5-1 unit/kg once daily, max: 80 units/day.
Subcutaneous injection once daily at the same time each day. Starting dose in insulin-naïve patients: 0.2 units/kg or 10 units once daily, titrated to achieve glycemic targets. Maximum single dose: 80 units per injection.
None Documented
None Documented
Terminal elimination half-life is 12.5 hours (range 10-18 hours) after subcutaneous administration due to prolonged absorption from the injection site, reflecting the duration of action.
Terminal half-life: 19 hours (range 14–24 hours) after subcutaneous administration due to slow absorption from injection site.
Renal (minimal, intact drug not excreted), metabolized to inactive metabolites excreted renally and fecally; unchanged insulin glargine does not undergo significant renal excretion, degradation products excreted renally (~30%) and fecally (~70%).
Renal excretion of degradation products; minimal intact insulin in urine. Fecal elimination is negligible.
Category C
Category C
Long-Acting Insulin
Long-Acting Insulin